Clinical Trials Directory

Trials / Terminated

TerminatedNCT06535009

Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors

A Phase I, Open-label, Uncontrolled, Dose Escalation Study to Evaluate the Tolerability and Safety of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Advanced or Metastatic Solid Tumors

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
25 (actual)
Sponsor
Ono Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
20 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This study is dose escalation study to evaluate the tolerability and safety of ONO-7914 alone and in combination with ONO-4538 in patients with advanced or metastatic solid tumors

Conditions

Interventions

TypeNameDescription
DRUGONO-7914Specified dose on specified days
DRUGONO-4538Specified dose on specified days

Timeline

Start date
2022-02-08
Primary completion
2025-02-26
Completion
2025-02-26
First posted
2024-08-02
Last updated
2025-06-04

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT06535009. Inclusion in this directory is not an endorsement.

Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors (NCT06535009) · Clinical Trials Directory